Literature DB >> 2590312

Sparteine oxidation polymorphism: phenotyping by measurement of sparteine and its dehydrometabolites in plasma.

W D Paar1, H Schuhler, R Fimmers, H J Dengler.   

Abstract

Phenotyping of the ability to oxidize sparteine was markedly facilitated by analyzing sparteine and dehydrosparteines in a single plasma sample by gas chromatography. The definitive identification of extensive and poor metabolizers was possible only 90 min after ingestion of 100 mg sparteine sulphate. In 121 healthy volunteers determination of the plasma level ratio was compared to the established determination of the metabolic ratio in urine. In each subject the alloted phenotype was the same by both methods. Plasma and urine analysis showed 9.9% of poor metabolizers.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2590312     DOI: 10.1007/bf00637735

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  21 in total

1.  The genetic polymorphism of sparteine metabolism.

Authors:  M Eichelbaum; K P Reetz; E K Schmidt; C Zekorn
Journal:  Xenobiotica       Date:  1986-05       Impact factor: 1.908

2.  The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine.

Authors:  L Bertilsson; A Aberg-Wistedt
Journal:  Br J Clin Pharmacol       Date:  1983-03       Impact factor: 4.335

3.  Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.

Authors:  M Eichelbaum; L Bertilsson; J Säwe; C Zekorn
Journal:  Clin Pharmacol Ther       Date:  1982-02       Impact factor: 6.875

4.  Pharmacokinetics of N-propylajmaline in relation to polymorphic sparteine oxidation.

Authors:  C Zekorn; G Achtert; H J Hausleiter; C H Moon; M Eichelbaum
Journal:  Klin Wochenschr       Date:  1985-11-15

5.  E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation.

Authors:  B Mellström; L Bertilsson; J Säwe; H U Schulz; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

6.  Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

Authors:  M Eichelbaum; N Spannbrucker; B Steincke; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

7.  Sparteine oxidation polymorphism: a family study.

Authors:  K Brøsen; S V Otton; L F Gram
Journal:  Br J Clin Pharmacol       Date:  1986-06       Impact factor: 4.335

8.  Evidence for altered catalytic properties of the cytochrome P-450 involved in sparteine oxidation in poor metabolizers.

Authors:  B Osikowska-Evers; P Dayer; U A Meyer; G M Robertz; M Eichelbaum
Journal:  Clin Pharmacol Ther       Date:  1987-03       Impact factor: 6.875

9.  Sparteine oxidation polymorphism in Denmark.

Authors:  K Brøsen; S V Otton; L F Gram
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1985-11

10.  Sparteine metabolism in Canadian Caucasians.

Authors:  A Vinks; T Inaba; S V Otton; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1982-01       Impact factor: 6.875

View more
  4 in total

Review 1.  Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping.

Authors:  D Frank; U Jaehde; U Fuhr
Journal:  Eur J Clin Pharmacol       Date:  2007-02-02       Impact factor: 2.953

Review 2.  Pharmacokinetic evaluation of herbal remedies. Basic introduction, applicability, current status and regulatory needs.

Authors:  P A De Smet; J R Brouwers
Journal:  Clin Pharmacokinet       Date:  1997-06       Impact factor: 6.447

3.  Genetically determined sparteine oxidation polymorphism in a Polish population.

Authors:  K Orzechowska-Juzwenko; J Pawlik; P Niewiński; P Milejski; J Dembowski; J Turek; A Goździk; L Swiebodzki; Z Hora
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

4.  Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations.

Authors:  G Alván; P Bechtel; L Iselius; U Gundert-Remy
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.